Search

Your search keyword '"Hogan, William J."' showing total 190 results

Search Constraints

Start Over You searched for: Author "Hogan, William J." Remove constraint Author: "Hogan, William J." Publisher american society of hematology Remove constraint Publisher: american society of hematology
190 results on '"Hogan, William J."'

Search Results

1. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis

2. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms

3. The utility of biomarkers in acute GVHD prognostication

4. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

5. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

6. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience

7. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival

8. Effective treatment of low-risk acute GVHD with itacitinib monotherapy

9. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

10. Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

11. Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

12. Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

13. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

14. Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

15. Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

16. IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

17. Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome

18. Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

19. Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

20. Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

21. Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

23. Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

24. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents

25. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

26. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning

27. Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN)

28. Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

29. Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy

30. Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90

31. Prognostic Value of Elafin in Acute Graft-Versus-Host Disease

32. T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML

33. Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents

34. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

35. Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias

36. Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study

37. Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents

39. Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

40. Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation

41. Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation

42. A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

43. Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis

44. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia

45. Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

46. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

47. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease

48. Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

50. Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes

Catalog

Books, media, physical & digital resources